Search Results - "Chari §, Ravi"

Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy by Chari, Ravi V. J., Miller, Michael L., Widdison, Wayne C.

“…Traditional cancer chemotherapy is often accompanied by systemic toxicity to the patient. Monoclonal antibodies against antigens on cancer cells offer an…”
Get full text

Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs by Chari, Ravi V. J

“…The therapeutic activity of most anticancer drugs in clinical use is limited by their general toxicity to proliferating cells, including some normal cells…”
Get full text

Antibody conjugate therapeutics: challenges and potential by Teicher, Beverly A, Chari, Ravi V J

“…Antibody conjugates are a diverse class of therapeutics consisting of a cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a…”
Get full text

Expanding the Reach of Antibody–Drug Conjugates by Chari, Ravi V. J

“…Antibody–drug conjugates (ADCs) represent an emerging new paradigm in cancer therapy. The approval of two ADCs has spurred considerable interest in this area…”
Get full text

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate by Lewis Phillips, Gail D, Li, Guangmin, Dugger, Debra L, Crocker, Lisa M, Parsons, Kathryn L, Mai, Elaine, Blättler, Walter A, Lambert, John M, Chari, Ravi V J, Lutz, Robert J, Wong, Wai Lee T, Jacobson, Frederic S, Koeppen, Hartmut, Schwall, Ralph H, Kenkare-Mitra, Sara R, Spencer, Susan D, Sliwkowski, Mark X

“…HER2 is a validated target in breast cancer therapy. Two drugs are currently approved for HER2-positive breast cancer: trastuzumab (Herceptin), introduced in…”
Get full text

Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer by Lambert, John M, Chari, Ravi V. J

“…Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the antitumor properties of the humanized anti-human epidermal growth factor…”
Get full text

A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity by Miller, Michael L, Fishkin, Nathan E, Li, Wei, Whiteman, Kathleen R, Kovtun, Yelena, Reid, Emily E, Archer, Katie E, Maloney, Erin K, Audette, Charlene A, Mayo, Michele F, Wilhelm, Alan, Modafferi, Holly A, Singh, Rajeeva, Pinkas, Jan, Goldmacher, Victor, Lambert, John M, Chari, Ravi V J

“…The promise of tumor-selective delivery of cytotoxic agents in the form of antibody-drug conjugates (ADC) has now been realized, evidenced by the approval of…”
Get full text

Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance by KOVTUN, Yelena V, AUDETTE, Charlene A, LAI, Katharine C, WIDDISON, Wayne C, KELLOGG, Brenda, JOHNSON, Holly, PINKAS, Jan, LUTZ, Robert J, SINGH, Rajeeva, GOLDMACHER, Victor S, CHARI, Ravi V. J, MAYO, Michele F, JONES, Gregory E, DOHERTY, Heather, MALONEY, Erin K, ERICKSON, Hans K, XIUXIA SUN, WILHELM, Sharon, AB, Olga

“…Conjugation of cytotoxic compounds to antibodies that bind to cancer-specific antigens makes these drugs selective in killing cancer cells. However, many of…”
Get full text

Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates by Zhao, Robert Y, Wilhelm, Sharon D, Audette, Charlene, Jones, Gregory, Leece, Barbara A, Lazar, Alexandru C, Goldmacher, Victor S, Singh, Rajeeva, Kovtun, Yelena, Widdison, Wayne C, Lambert, John M, Chari, Ravi V. J

“…The synthesis and biological evaluation of hydrophilic heterobifunctional cross-linkers for conjugation of antibodies with highly cytotoxic agents are…”
Get full text

Disulfide-Linked Antibody−Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage by Kellogg, Brenda A, Garrett, Lisa, Kovtun, Yelena, Lai, Katharine C, Leece, Barbara, Miller, Michael, Payne, Gillian, Steeves, Rita, Whiteman, Kathleen R, Widdison, Wayne, Xie, Hongsheng, Singh, Rajeeva, Chari, Ravi V. J, Lambert, John M, Lutz, Robert J

“…In this report, we describe the synthesis of a panel of disulfide-linked huC242 (anti-CanAg) antibody maytansinoid conjugates (AMCs), which have varying levels…”
Get full text

Optimizing Lysosomal Activation of Antibody–Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers by Salomon, Paulin L, Reid, Emily E, Archer, Katie E, Harris, Luke, Maloney, Erin K, Wilhelm, Alan J, Miller, Michael L, Chari, Ravi V. J, Keating, Thomas A, Singh, Rajeeva

“…Although peptide linkers are used in multiple clinical-stage ADCs, there are only few reports on optimizing peptide linkers for efficient lysosomal proteolysis…”
Get full text

A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs) by Miller, Michael L, Shizuka, Manami, Wilhelm, Alan, Salomon, Paulin, Reid, Emily E, Lanieri, Leanne, Sikka, Surina, Maloney, Erin K, Harvey, Lauren, Qiu, Qifeng, Archer, Katie E, Bai, Chen, Vitharana, Dilrukshi, Harris, Luke, Singh, Rajeeva, Ponte, Jose F, Yoder, Nicholas C, Kovtun, Yelena, Lai, Katharine C, Ab, Olga, Pinkas, Jan, Keating, Thomas A, Chari, Ravi V J

“…Tumor-selective delivery of cytotoxic agents in the form of antibody-drug conjugates (ADCs) is now a clinically validated approach for cancer treatment. In an…”
Get full text

A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells by Kovtun, Yelena, Jones, Gregory E., Adams, Sharlene, Harvey, Lauren, Audette, Charlene A., Wilhelm, Alan, Bai, Chen, Rui, Lingyun, Laleau, Rassol, Liu, Fenghua, Ab, Olga, Setiady, Yulius, Yoder, Nicholas C., Goldmacher, Victor S., Chari, Ravi V.J., Pinkas, Jan, Chittenden, Thomas

“…The outlook for patients with refractory/relapsed acute myeloid leukemia (AML) remains poor, with conventional chemotherapeutic treatments often associated…”
Get full text

Antibody–Drug Conjugates with Indolinobenzodiazepine Dimer Payloads: DNA-Binding Mechanism of Indolinobenzodiazepine Dimer Catabolites in Target Cancer Cells by Singh, Rajeeva, Reid, Emily E, Harris, Luke, Salomon, Paulin L, Miller, Michael L, Chari, Ravi V. J, Keating, Thomas A

“…DNA-targeting indolinobenzodiazepine dimer (IGN) payloads are used in several clinical-stage antibody–drug conjugates. IGN drugs alkylate DNA through the…”
Get full text

Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer by Widdison, Wayne C, Wilhelm, Sharon D, Cavanagh, Emily E, Whiteman, Kathleen R, Leece, Barbara A, Kovtun, Yelena, Goldmacher, Victor S, Xie, Hongsheng, Steeves, Rita M, Lutz, Robert J, Zhao, Robert, Wang, Lintao, Blättler, Walter A, Chari, Ravi V. J

“…Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clinical trials because of unacceptable systemic toxicity. The potent…”
Get full text

Synthesis and Biological Evaluation of Antibody Conjugates of Phosphate Prodrugs of Cytotoxic DNA Alkylators for the Targeted Treatment of Cancer by Zhao, Robert Yongxin, Erickson, Hans K, Leece, Barbara A, Reid, Emily E, Goldmacher, Victor S, Lambert, John M, Chari, Ravi V. J

“…The synthesis and biological evaluation of phosphate prodrugs of analogues of 1 (CC-1065) and their conjugates with antibodies are described. The phosphate…”
Get full text

A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells by Singh, Rajeeva, Setiady, Yulius Y, Ponte, Jose, Kovtun, Yelena V, Lai, Katharine C, Hong, E Erica, Fishkin, Nathan, Dong, Ling, Jones, Gregory E, Coccia, Jennifer A, Lanieri, Leanne, Veale, Karen, Costoplus, Juliet A, Skaletskaya, Anna, Gabriel, Rabih, Salomon, Paulin, Wu, Rui, Qiu, Qifeng, Erickson, Hans K, Lambert, John M, Chari, Ravi V J, Widdison, Wayne C

“…A triglycyl peptide linker (CX) was designed for use in antibody -: drug conjugates (ADC), aiming to provide efficient release and lysosomal efflux of…”
Get full text

Synthesis and Evaluation of Camptothecin Antibody–Drug Conjugates by Li, Wei, Veale, Karen H, Qiu, Qifeng, Sinkevicius, Kerstin W, Maloney, Erin K, Costoplus, Juliet A, Lau, Janet, Evans, Helen L, Setiady, Yulius, Ab, Olga, Abbott, Stephen M, Lee, Jenny, Wisitpitthaya, Somsinee, Skaletskaya, Anna, Wang, Lintao, Keating, Thomas A, Chari, Ravi V. J, Widdison, Wayne C

“…Antibody–drug conjugates (ADCs) that incorporate the exatecan derivative DXd in their payload are showing promising clinical results in solid tumor…”
Get full text

Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing by Widdison, Wayne C, Ponte, Jose F, Coccia, Jennifer A, Lanieri, Leanne, Setiady, Yulius, Dong, Ling, Skaletskaya, Anna, Hong, E. Erica, Wu, Rui, Qiu, Qifeng, Singh, Rajeeva, Salomon, Paulin, Fishkin, Nathan, Harris, Luke, Maloney, Erin K, Kovtun, Yelena, Veale, Karen, Wilhelm, Sharon D, Audette, Charlene A, Costoplus, Juliet A, Chari, Ravi V. J

“…Antibody anilino maytansinoid conjugates (AaMCs) have been prepared in which a maytansinoid bearing an aniline group was linked through the aniline amine to a…”
Get full text

The International Position on Laparoscopic Liver Surgery: The Louisville Statement, 2008 by BUELL, Joseph F, CHERQUI, Daniel, WAKABAYASHI, Go, BELLI, Giulio, KANEKO, Hironori, KER, Chen-Guo, SCATTON, Olivier, LAURENT, Alexis, ABDALLA, Eddie K, CHAUDHURY, Prosanto, DUTSON, Erik, GAMBLIN, Clark, GELLER, David A, D'ANGELICA, Michael, NAGORNEY, David, TESTA, Giuliano, LABOW, Daniel, MANAS, Derrik, POON, Ronnie T, NELSON, Heidi, MARTIN, Robert, CLARY, Bryan, PINSON, Wright C, O' ROURKE, Nicholas, MARTINIE, John, VAUTHEY, Jean-Nicolas, GOLDSTEIN, Robert, ROAYAIE, Sasan, BARLET, David, ESPAT, Joseph, ABECASSIS, Michael, REES, Myrddin, YUMAN FONG, MCMASTERS, Kelly M, IANNITTI, David, BROELSCH, Christoph, BUSUTTIL, Ron, BELGHITI, Jacques, STRASBERG, Steven, CHARI, Ravi S, DAGHER, Ibrahim, KOFFRON, Alan J, THOMAS, Mark, GAYET, Brice, HO SEONG HAN

“…To summarize the current world position on laparoscopic liver surgery. Multiple series have reported on the safety and efficacy of laparoscopic liver surgery…”
Get full text